Brooklyn ImmunoTherapeutics (NYSEAMERICAN:BTX) Price Target Lowered to $5.00 at Maxim Group

Brooklyn ImmunoTherapeutics (NYSEAMERICAN:BTXGet Rating) had its price target cut by research analysts at Maxim Group from $9.00 to $5.00 in a report issued on Wednesday, The Fly reports. Maxim Group’s price objective suggests a potential upside of 252.11% from the stock’s current price.

Separately, Cantor Fitzgerald assumed coverage on shares of Brooklyn ImmunoTherapeutics in a research note on Wednesday, December 29th. They set an “overweight” rating and a $9.00 price target for the company.

NYSEAMERICAN BTX opened at $1.42 on Wednesday. Brooklyn ImmunoTherapeutics has a 12 month low of $1.40 and a 12 month high of $80.67.

Brooklyn ImmunoTherapeutics (NYSEAMERICAN:BTXGet Rating) last issued its quarterly earnings results on Friday, April 15th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.03).

Hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada acquired a new stake in shares of Brooklyn ImmunoTherapeutics in the second quarter valued at about $29,000. Citigroup Inc. increased its holdings in Brooklyn ImmunoTherapeutics by 161.1% during the 3rd quarter. Citigroup Inc. now owns 3,742 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 2,309 shares in the last quarter. ProShare Advisors LLC purchased a new position in Brooklyn ImmunoTherapeutics during the 4th quarter valued at about $58,000. Strs Ohio increased its holdings in Brooklyn ImmunoTherapeutics by 23.6% during the 3rd quarter. Strs Ohio now owns 6,800 shares of the biotechnology company’s stock valued at $63,000 after acquiring an additional 1,300 shares in the last quarter. Finally, UBS Group AG purchased a new position in Brooklyn ImmunoTherapeutics during the 3rd quarter valued at about $71,000.

Brooklyn ImmunoTherapeutics Company Profile (Get Rating)

Brooklyn ImmunoTherapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.

Recommended Stories

The Fly logo

Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.